Eduovisual
Renal & Urinary
Hyperphosphatemia and hypophosphatemia: causes and treatment
— Normal serum phosphate: 2.5–4.5 mg/dL in adults (higher in children, up to 6–7 mg/dL in infants)
— 85% stored in bone, 14% intracellular, ~1% extracellular
— Regulated by PTH (phosphaturic), FGF-23 (phosphaturic, also suppresses calcitriol), calcitriol (increases gut absorption), and dietary intake
— Kidney is the master regulator via proximal tubule NaPi-2a/2c cotransporters
— Any patient with CKD stage 3b–5 or on dialysis
— Tumor lysis syndrome (hematologic malignancy + chemotherapy)
— Rhabdomyolysis, crush injury, severe hemolysis
— Tetany or paresthesias with concurrent hypocalcemia (reciprocal relationship)
— Vascular/soft-tissue calcifications, calciphylaxis in ESRD
— Refeeding syndrome in malnourished, alcoholic, anorexic, or post-bariatric patients
— DKA during insulin therapy (intracellular shift)
— Chronic alcoholism, sepsis, severe respiratory alkalosis
— Prolonged TPN without phosphate repletion
— Proximal tubular dysfunction (Fanconi syndrome, tenofovir, ifosfamide)
— Unexplained muscle weakness, rhabdomyolysis, respiratory failure on weaning from ventilator
— "Could not be weaned from ventilator" → check phosphate
— "Started TPN 3 days ago, now confused" → refeeding
— "ESRD with itching and calcified vessels on KUB" → hyperphosphatemia
— "Chemotherapy yesterday, now oliguric with tetany" → tumor lysis
Board pearl: Always interpret phosphate in the context of calcium, PTH, vitamin D, and renal function—isolated phosphate values are nearly meaningless. The Ca × P product >55 mg²/dL² predicts metastatic calcification and is a key driver of management urgency in CKD.
Step 3 management: In outpatient CKD, target phosphate toward the normal range using dietary counseling first, binders second, and only initiate cinacalcet/calcimimetics when PTH remains elevated despite phosphate control.
— Often asymptomatic; symptoms come from concurrent hypocalcemia
— Perioral numbness, carpopedal spasm, Chvostek/Trousseau signs, tetany, seizures
— Tumor lysis: 12–72 hours post-chemo, hyperuricemia, hyperkalemia, hypocalcemia, AKI
— Rhabdomyolysis: dark urine, myalgia, recent crush/statin/cocaine use
— Pruritus (often severe, intractable)
— Bone pain, fractures (renal osteodystrophy)
— Vascular stiffness, accelerated atherosclerosis
— Calciphylaxis: painful, violaceous, necrotic skin lesions in ESRD
— Red-eye from conjunctival calcium-phosphate deposits
— Muscle weakness, including diaphragm → respiratory failure, vent weaning failure
— Rhabdomyolysis, hemolysis (low ATP in RBCs)
— Encephalopathy, seizures, coma
— Heart failure (decreased myocardial contractility from low ATP/2,3-BPG)
— Bone pain, osteomalacia, pseudofractures (Looser zones)
— Proximal muscle weakness, waddling gait
— In children: rickets (genu varum, rachitic rosary, delayed fontanelle closure)
— Diet history: alcohol use, recent NPO status, eating disorder, bariatric surgery
— Medications: antacids (aluminum/calcium-based binders, sevelamer), tenofovir, ifosfamide, imatinib, intravenous iron (FCM), bisphosphonates
— Recent chemotherapy, transfusions, dialysis schedule
— Family history: X-linked hypophosphatemic rickets, tumor-induced osteomalacia
Key distinction: Acute hypophosphatemia symptoms correlate with rate of fall and intracellular depletion, not just absolute number. A patient with chronic hypophosphatemia at 1.5 mg/dL may be asymptomatic, while a refed alcoholic dropping from 3.0 to 1.5 may decompensate.
Board pearl: Ferric carboxymaltose (Injectafer) causes a uniquely severe and prolonged hypophosphatemia via FGF-23 elevation—check phosphate 1–2 weeks post-infusion.
— Chvostek sign: tap facial nerve anterior to ear → ipsilateral facial twitch (low specificity, present in 10% of normals)
— Trousseau sign: BP cuff inflated above systolic for 3 min → carpopedal spasm (more specific)
— Hyperreflexia, perioral tingling
— Prolonged QT interval on ECG → risk of torsades
— Excoriations from uremic pruritus
— Subcutaneous calcified nodules (tumoral calcinosis)
— Calciphylaxis: livedo reticularis progressing to retiform purpura and black eschar, exquisitely tender, often on adipose-rich areas (thighs, abdomen)
— Band keratopathy at the medial/lateral limbus
— Brown tumors of secondary hyperparathyroidism
— Proximal muscle weakness: difficulty rising from chair, climbing stairs
— Diminished diaphragmatic excursion, paradoxical breathing
— Decreased deep tendon reflexes (severe)
— Altered mental status, asterixis (severe)
— In rickets: bowing of long bones, frontal bossing, widened wrists/ankles, rachitic rosary at costochondral junctions
— Hypotension and reduced cardiac output in severe hypophosphatemia (<1.0 mg/dL)
— Assess volume status before phosphate repletion (avoid pulmonary edema with IV potassium phosphate)
— Cardiac monitoring if phosphate <1.5 mg/dL
— Negative inspiratory force (NIF) and vital capacity in patients failing vent wean
— Skin biopsy for suspected calciphylaxis (calcium deposits in small vessels with intimal hyperplasia)
CCS pearl: In a CCS case of "failure to wean from ventilator," after ruling out usual suspects (sedation, fluid overload, infection), order serum phosphate, magnesium, and potassium—all three depletions impair respiratory muscle function.
Board pearl: Calciphylaxis carries 1-year mortality >50%; recognize early, stop warfarin/calcium-based binders, and consult nephrology for sodium thiosulfate.
— Serum phosphate, calcium (total and ionized), magnesium
— BUN, creatinine, eGFR
— Albumin (corrected calcium = measured Ca + 0.8 × [4 − albumin])
— Intact PTH
— 25-OH vitamin D and 1,25-(OH)₂ vitamin D
— CBC, basic metabolic panel
— Urinalysis with urine phosphate, calcium, creatinine, glucose, protein
— FEPO₄ = (urine PO₄ × serum Cr) / (serum PO₄ × urine Cr) × 100
— TmP/GFR (tubular maximum reabsorption) — best test for renal phosphate wasting
— In hypophosphatemia:
— FEPO₄ <5% or 24-hr urine PO₄ <100 mg → non-renal cause (GI loss, intracellular shift)
— FEPO₄ >5% or TmP/GFR low → renal phosphate wasting
— Suspected refeeding: phosphate, K, Mg, glucose daily × 5–7 days after initiating feeds
— Suspected tumor lysis: uric acid, LDH, K, Ca, phosphate q6–8h
— Suspected rhabdomyolysis: CK, urine myoglobin
— Suspected Fanconi: urine glucose (with normal serum glucose), proteinuria (LMW), bicarbonate, uric acid
— Suspected oncogenic osteomalacia: FGF-23 level
— Hyperphosphatemia → hypocalcemia → prolonged QT, possible torsades
— Severe hypophosphatemia → arrhythmias, decreased contractility
— KUB and lateral abdominal X-ray: vascular calcifications
— Bone X-rays: rickets, osteomalacia (Looser zones), brown tumors
— DEXA for chronic phosphate wasting
Step 3 management: When evaluating new hypophosphatemia, always measure urine phosphate before repletion—repletion changes the urine value and obscures the diagnosis.
Board pearl: Pseudohypophosphatemia can occur with paraproteinemia, mannitol, or high bilirubin interfering with the assay—repeat with a different method if clinically unexplained.
— Step 1: Check urine PO₄ (FEPO₄ or 24-hr)
— Step 2: If renal wasting → check PTH
— High PTH + low calcium → secondary hyperparathyroidism (vitamin D deficiency)
— High PTH + high calcium → primary hyperparathyroidism
— Normal PTH + glycosuria/aminoaciduria/proximal RTA → Fanconi syndrome
— Normal PTH + isolated phosphate wasting → check FGF-23
— High FGF-23 + adult onset → tumor-induced osteomalacia (mesenchymal tumor; image with ⁶⁸Ga-DOTATATE PET)
— High FGF-23 + familial → X-linked hypophosphatemic rickets (PHEX mutation), autosomal dominant HR
— Step 3: If non-renal → GI loss (diarrhea, malabsorption, antacid binding) or shift (refeeding, insulin, respiratory alkalosis, hungry bone syndrome)
— Confirm not pseudohyperphosphatemia (hemolyzed sample, heparin, paraproteins)
— Assess GFR — most cases are CKD-related
— If normal GFR:
— Acute release: tumor lysis, rhabdomyolysis, hemolysis
— Increased intake: phosphate-containing enemas (Fleet), bowel prep
— Hypoparathyroidism (low PTH, low Ca, high PO₄)
— Pseudohypoparathyroidism (high PTH, low Ca, high PO₄; Albright hereditary osteodystrophy features)
— Vitamin D toxicity (high Ca, high PO₄, low PTH)
— Acromegaly (GH increases tubular reabsorption)
— Bisphosphonate use, tumoral calcinosis
— Genetic testing for FGF-23 disorders, PHEX, GNAS
— Bone biopsy with tetracycline labeling for osteomalacia confirmation
— 24-hr urine collection for stone-formers with hypophosphatemia
Key distinction: Hypoparathyroidism vs pseudohypoparathyroidism—both have low Ca and high PO₄, but pseudohypoparathyroidism has elevated PTH (end-organ resistance) and may show short 4th/5th metacarpals, round facies, short stature (AHO phenotype).
Board pearl: Fleet enema-induced hyperphosphatemia in elderly or renal-impaired patients can be fatal—causes severe hypocalcemia, hypotension, and arrest. Avoid in CKD and bowel obstruction.
— Mild: 2.0–2.5 mg/dL — usually asymptomatic, oral repletion
— Moderate: 1.0–1.9 mg/dL — symptomatic possible, oral or IV depending on cause
— Severe: <1.0 mg/dL — IV repletion mandatory, monitor closely
— Symptomatic at any level (rhabdo, hemolysis, respiratory failure) → IV
— Acute >5 mg/dL with symptoms (hypocalcemia, AKI) → urgent treatment
— Chronic in CKD: KDIGO targets — "toward the normal range" (no longer a strict 3.5–5.5 cutoff in dialysis)
— Severe with Ca × P > 70 or symptomatic hypocalcemia → consider dialysis
— Identify and remove precipitant (stop tenofovir, hold ferric carboxymaltose, treat alcoholism)
— Replete magnesium first if low (refractory phosphate replacement without Mg correction)
— Oral preferred when phosphate >1.5 and asymptomatic — fewer complications
— IV reserved for severe, symptomatic, or NPO patients
— Acute non-CKD: IV saline + insulin/dextrose if hypocalcemic, dialysis if severe AKI/oliguric
— Tumor lysis: aggressive IV fluids, rasburicase for uric acid, dialysis if oliguric
— Chronic CKD:
1. Dietary phosphate restriction (800–1000 mg/day; avoid processed foods, cola, dairy excess)
2. Phosphate binders with meals
3. Adjust dialysis prescription if applicable
4. Treat secondary hyperparathyroidism (calcitriol analogs, calcimimetics)
— Severe symptomatic hypophosphatemia → telemetry, IV repletion, q6h labs
— Tumor lysis with hyperphosphatemia → ICU or step-down, q6h chemistries
— Fleet enema overdose → ED resuscitation, dialysis consult if severe
Step 3 management: In CKD-MBD outpatient follow-up, check phosphate, calcium, PTH every 1–3 months in stage 5/dialysis; every 3–6 months in stage 4. Trends matter more than single values.
CCS pearl: Always repeat phosphate 4–6 hours after IV repletion and at 24 hours to assess response and avoid rebound hyperphosphatemia.
— K-Phos Neutral (250 mg phosphate per tab): 1–2 tabs 3–4× daily
— Phospha 250 Neutral, Neutra-Phos: similar dosing
— Skim/whole milk: ~250 mg phosphate per cup (cheap, well-tolerated)
— Side effects: diarrhea (dose-limiting), nausea, hyperkalemia (with K-phos), hypocalcemia
— Avoid in hypercalcemia (precipitates calcium-phosphate)
— Sodium phosphate or potassium phosphate (1 mmol PO₄ = ~31 mg)
— Typical dosing:
— PO₄ 1.0–1.9 mg/dL: 0.16–0.32 mmol/kg over 4–6 hours
— PO₄ <1.0 mg/dL: 0.32–0.64 mmol/kg over 4–6 hours
— Maximum infusion rate: 7 mmol/hr (faster → hypocalcemia, arrhythmia, calcification)
— Use K-phos if K <4, Na-phos if K ≥4 or hyperkalemia risk
— Monitor PO₄, Ca, K, Mg q6h during repletion
— Take with meals — bind dietary phosphate in gut
— Calcium-based (calcium carbonate, calcium acetate/PhosLo)
— Cheap, effective
— Risk: hypercalcemia, vascular calcification — limit elemental Ca <1500 mg/day
— Preferred in hypocalcemic, low-PTH patients
— Non-calcium-based (preferred when Ca high, vascular calcification, or low PTH)
— Sevelamer (carbonate or HCl): also lowers LDL; GI side effects
— Lanthanum carbonate: chewable; long-term tissue deposition concern
— Ferric citrate: also replenishes iron
— Sucroferric oxyhydroxide: low pill burden
— Aluminum hydroxide: short-term only; chronic use → encephalopathy, osteomalacia
— Calcimimetics (cinacalcet, etelcalcetide): lower PTH, Ca, and phosphate in secondary HPT
— Active vitamin D (calcitriol, paricalcitol): lowers PTH but raises Ca and PO₄ — balance carefully
— Burosumab (anti-FGF-23 monoclonal): X-linked hypophosphatemic rickets, tumor-induced osteomalacia
Board pearl: Sevelamer is preferred over calcium-based binders in dialysis patients with vascular calcification, hypercalcemia, or adynamic bone disease (low PTH). Multiple trials show reduced calcification progression.
Step 3 management: When prescribing binders, counsel patients to take with the first bite of each meal—taking between meals provides no benefit and is the most common adherence failure.
— Symptomatic hypocalcemia refractory to calcium repletion
— Oliguric AKI with rising phosphate (tumor lysis, rhabdomyolysis)
— Severe Fleet enema toxicity in CKD
— Phosphate >10 mg/dL with end-organ symptoms
— Note: hemodialysis removes ~800 mg/session; phosphate rebounds from intracellular stores, so multiple or extended sessions may be needed
— Increase frequency (nocturnal, short daily HD removes more phosphate)
— Longer treatment time (4 vs 3 hours)
— High-flux membranes
— Peritoneal dialysis less effective for phosphate
— Address dietary nonadherence — most common cause of "refractory" hyperphosphatemia
— Persistent PTH >800 pg/mL despite maximum medical therapy
— Severe hypercalcemia or hyperphosphatemia refractory to binders/calcimimetics
— Calciphylaxis
— Severe bone disease, fractures
— Subtotal (3.5-gland) or total with autotransplant
— Stop warfarin (switch to apixaban if anticoagulation needed)
— Stop calcium-based binders, calcitriol, iron
— Sodium thiosulfate 25 g IV 3× weekly after HD
— Aggressive wound care, pain control, hyperbaric O₂ in some centers
— Cinacalcet to suppress PTH
— Optimize dialysis with low-calcium dialysate
— Tumor-induced osteomalacia: surgical resection of FGF-23–producing mesenchymal tumor (curative)
— If unresectable: burosumab (anti-FGF-23 antibody) or oral phosphate + calcitriol
— X-linked hypophosphatemic rickets: burosumab first-line (replaces older phosphate + calcitriol regimens)
— Tumor lysis prophylaxis: IV hydration 3 L/m²/day, allopurinol or rasburicase (high-risk), avoid potassium and phosphate in IVF
— Monitor q6h chemistries × 48–72 hours post-chemo
CCS pearl: In tumor lysis with hyperphosphatemia, do NOT give calcium for asymptomatic hypocalcemia—Ca × P product spike causes metastatic calcification. Reserve Ca for symptomatic tetany or arrhythmia.
Board pearl: Burosumab has revolutionized XLH treatment, with superior outcomes vs conventional phosphate/calcitriol.
— Reduced GFR with normal creatinine (sarcopenia) → adjust binder dosing, watch for toxicity
— Polypharmacy: PPIs reduce calcium absorption; antacids cause phosphate binding (chronic Mg/Al toxicity)
— Fleet enema contraindicated in elderly with CKD — fatal hyperphosphatemia reported
— Fragility fracture risk: balance phosphate control with bone health
— Adherence challenges with pill burden — prefer lower-pill-count binders (sucroferric oxyhydroxide, lanthanum chewable)
— Phosphate retention begins in CKD 3b (eGFR <45)
— FGF-23 rises first, then PTH, then phosphate becomes overt
— KDIGO 2017 update: maintain phosphate toward normal range; don't reflexively start binders for mildly elevated levels — dietary counseling first
— Avoid hyperphosphatemia-driven vascular calcification by addressing early
— Phosphate target: lower elevated levels toward normal; avoid aggressive lowering that causes hypophosphatemia (also harmful)
— Use non-calcium binders if: persistent hypercalcemia, arterial calcification, adynamic bone, PTH <150
— Monitor Ca, P monthly; PTH every 3 months
— Cinacalcet/etelcalcetide for PTH >300 despite control of Ca/P
— Hyperphosphatemia common in oliguric AKI
— CRRT removes phosphate efficiently; may cause hypophosphatemia with prolonged CRRT (>48–72 hours) — supplement phosphate in replacement fluid or separately
— Monitor phosphate q12h during CRRT
— Hypophosphatemia common in cirrhosis (poor intake, alcoholism, refeeding when admitted)
— Hepatic resection causes profound hypophosphatemia (regenerating liver consumes phosphate) — anticipate and replete
— TPN in liver failure: include phosphate, monitor daily
— Renal transplant recipients often develop post-transplant hypophosphatemia (persistent FGF-23 elevation + tubular dysfunction)
— Usually resolves over 6–12 months; replete orally
— Avoid IV calcitriol unless symptomatic — can suppress new graft function
Step 3 management: In CKD stage 4 outpatient, address phosphate, vitamin D, and PTH before dialysis initiation—established vascular calcification is irreversible.
Board pearl: Prolonged CRRT (>72 hr) is a common cause of iatrogenic hypophosphatemia in ICU—add phosphate to replacement fluid or supplement separately.
— Phosphate requirements increase modestly; serum levels stable
— Severe hyperemesis gravidarum can cause refeeding-like hypophosphatemia when nutrition resumed
— Pre-eclampsia not classically associated with phosphate disorders
— Phosphate binders in pregnancy with CKD: calcium-based preferred (sevelamer/lanthanum lack pregnancy data, Category C)
— Cinacalcet: limited data, generally avoided
— Burosumab: Category not established; weigh risk-benefit in pregnant XLH patients
— Calcium-based binders preferred
— Active vitamin D analogs cross into breast milk — monitor infant calcium
— Rickets: most common manifestation of chronic hypophosphatemia
— Nutritional rickets: vitamin D deficiency (most common globally)
— X-linked hypophosphatemic rickets (XLH): most common heritable form, PHEX mutation, high FGF-23
— Features: short stature, genu varum/valgum, dental abscesses, enthesopathy
— Treatment: burosumab (preferred over phosphate + calcitriol since 2018)
— Autosomal dominant HR (FGF23 mutation), autosomal recessive HR (DMP1, ENPP1)
— Hereditary hypophosphatemic rickets with hypercalciuria (HHRH): SLC34A3 — treat with phosphate alone (no calcitriol)
— Normal pediatric phosphate higher than adults (bone growth)
— Tumor lysis in pediatric ALL/Burkitt lymphoma — give rasburicase, avoid phosphate/K in fluids
— Pediatric CKD-MBD: growth retardation, rachitic deformities; treat aggressively
— Avoid Fleet enemas in young children
— Hypocalcemia of prematurity often paired with relative hyperphosphatemia
— Late neonatal hypocalcemia from high-phosphate cow's milk formula
— Premature infants on TPN: phosphate repletion essential to prevent metabolic bone disease of prematurity
— Pediatric IV phosphate: 0.15–0.33 mmol/kg over 4–6 hours
— Oral: 30–90 mg/kg/day elemental phosphate divided
Board pearl: A child with bowed legs, short stature, normal calcium, low phosphate, and family history → X-linked hypophosphatemic rickets (PHEX). First-line is now burosumab, not phosphate + calcitriol.
Step 3 management: Children on chronic phosphate therapy require monitoring for secondary hyperparathyroidism and nephrocalcinosis — annual renal ultrasound and PTH.
— Hypocalcemia (precipitation as calcium-phosphate) → tetany, seizures, prolonged QT, torsades
— Vascular calcification: medial arterial calcification (Mönckeberg), accelerated atherosclerosis
— Calciphylaxis: 1-year mortality >50%
— Renal osteodystrophy: high-turnover (osteitis fibrosa) or low-turnover (adynamic) bone disease
— Soft-tissue/tumoral calcinosis (joints, conjunctiva, viscera)
— Pruritus, refractory to antihistamines
— Increased all-cause and cardiovascular mortality in CKD (linear relationship above 5 mg/dL)
— Secondary → tertiary hyperparathyroidism requiring parathyroidectomy
— Respiratory failure from diaphragmatic weakness — failure to wean from ventilator
— Rhabdomyolysis (especially in alcoholics being refed)
— Hemolysis (low RBC ATP)
— Cardiac dysfunction: decreased contractility, arrhythmias, reversible cardiomyopathy
— Encephalopathy: confusion, seizures, coma at <1.0 mg/dL
— Refeeding syndrome: hypophosphatemia + hypokalemia + hypomagnesemia + thiamine deficiency + fluid overload → cardiac arrest, Wernicke
— Chronic: osteomalacia, pseudofractures, proximal myopathy
— Impaired immune function (decreased phagocytosis), platelet dysfunction
— Rapid IV phosphate infusion: hypocalcemia, hypotension, hyperkalemia (K-phos), metastatic calcification, AKI
— Aluminum binder chronic use: dementia, osteomalacia, microcytic anemia
— Calcium-based binders: hypercalcemia, vascular calcification
— Calcitriol: hypercalcemia, hyperphosphatemia worsening, vascular calcification
— Fleet enema in CKD: severe hyperphosphatemia, hypocalcemia, AKI, death
— Cinacalcet: hypocalcemia, QT prolongation
— Hyperphosphatemia in dialysis: every 1 mg/dL above 5 → 18% increased mortality
— Aggressive phosphate control improves bone outcomes but mortality benefit uncertain
— Calciphylaxis prevention is far better than treatment
Board pearl: Refeeding syndrome mortality comes primarily from severe hypophosphatemia causing cardiac and respiratory failure. Start feeds at 10–20 kcal/kg/day, advance slowly over 5–7 days, replete electrolytes daily, give thiamine before glucose.
Key distinction: Adynamic bone disease (low PTH, low turnover) is worsened by aggressive PTH suppression — fractures, hypercalcemia, calcification all increase.
— Symptomatic hypocalcemia with arrhythmia (prolonged QT, torsades)
— Acute hyperphosphatemia with oliguric AKI (tumor lysis, rhabdomyolysis, Fleet toxicity)
— Calciphylaxis with sepsis or extensive wounds
— Hemodynamic instability from hypocalcemia
— Severe tumor lysis syndrome (Cairo-Bishop laboratory + clinical criteria)
— Phosphate <1.0 mg/dL regardless of symptoms (cardiac and respiratory risk)
— Respiratory failure/failure to wean attributed to phosphate
— Rhabdomyolysis, hemolysis, or arrhythmia from hypophosphatemia
— Severe refeeding syndrome with multiple electrolyte derangements
— Altered mental status, seizures
— Nephrology: CKD-MBD management, calciphylaxis, refractory hyperphosphatemia, AKI requiring dialysis, tumor lysis
— Endocrinology: hyperparathyroidism evaluation, XLH/tumor-induced osteomalacia, complex bone disease
— Oncology/heme: tumor lysis prophylaxis and management, suspected occult mesenchymal tumor in tumor-induced osteomalacia
— Surgery/ENT: parathyroidectomy for tertiary HPT
— Wound care/plastic surgery: calciphylaxis lesions
— Genetics: suspected heritable phosphate disorder
— Nutrition/dietitian: dietary phosphate education, refeeding plans
— Floor → step-down if phosphate <1.5 with symptoms, requiring frequent labs
— Floor → ICU if hemodynamic compromise, arrhythmia, respiratory failure
— ED → dialysis-capable hospital for severe acute hyperphosphatemia in oliguric AKI
— Pediatric XLH or tumor-induced osteomalacia → tertiary center with burosumab access
— Phosphate trending appropriately × 24 hours
— Stable on oral repletion or established binder regimen
— Underlying cause addressed
— Outpatient follow-up arranged within 1–2 weeks (CKD-MBD) or sooner
CCS pearl: In a CCS case with tumor lysis, advance the clock in 4–6 hour increments and re-check labs each cycle; order rasburicase, IVF, dialysis consult, and avoid potassium/phosphate-containing fluids until normalized.
Step 3 management: Don't discharge a refeeding-syndrome patient until phosphate stable >2.0 for 48 hours off IV repletion and caloric goals advanced safely.
— Decreased excretion
— CKD (most common, by far)
— AKI, especially oliguric
— Hypoparathyroidism (post-thyroidectomy, autoimmune, DiGeorge)
— Pseudohypoparathyroidism (PTH resistance)
— Acromegaly, tumoral calcinosis
— Bisphosphonate use
— Increased intake/absorption
— Vitamin D toxicity
— Phosphate-containing enemas, laxatives, bowel preps
— Excess milk/dairy in CKD
— Cellular release
— Tumor lysis syndrome
— Rhabdomyolysis, crush injury
— Hemolysis (intravascular)
— Lactic acidosis, DKA (less prominent)
— Pseudohyperphosphatemia
— Hemolyzed sample, paraproteinemia, hyperbilirubinemia, heparin, liposomal amphotericin B
— Intracellular shift (most common, often transient)
— Refeeding syndrome
— Insulin therapy in DKA
— Respiratory alkalosis (sepsis, anxiety, salicylate toxicity)
— Hungry bone syndrome post-parathyroidectomy
— Catecholamine surge
— Decreased GI absorption
— Chronic diarrhea, malabsorption
— Phosphate binders (any cause, including OTC antacids)
— Vitamin D deficiency
— Chronic alcoholism (combined intake + shift + renal wasting)
— Increased renal excretion
— Hyperparathyroidism (primary, secondary)
— FGF-23-mediated: XLH, autosomal HR, tumor-induced osteomalacia
— Fanconi syndrome (multiple causes — see below)
— Drug-induced: tenofovir, ifosfamide, imatinib, cisplatin, ferric carboxymaltose
— Volume expansion, diuretics (mild)
— Post-renal transplant
Key distinction: Primary hyperparathyroidism: high Ca, low PO₄, high PTH. Secondary hyperparathyroidism (vitamin D def or CKD): low/normal Ca, low/normal PO₄ (deficiency) or high PO₄ (CKD), high PTH. Tertiary (long-standing CKD): high Ca, high PO₄, very high PTH (autonomous).
Board pearl: Ferric carboxymaltose (IV iron) causes severe FGF-23–mediated hypophosphatemia that can persist for weeks — increasingly common cause; check phosphate 1–2 weeks after infusion in symptomatic patients.
— Hypokalemia
— Hypomagnesemia
— Hypocalcemia
— Hypothyroidism, hyperthyroidism (proximal myopathy)
— Statin myopathy
— Polymyositis/dermatomyositis
— Guillain-Barré
— Myasthenia gravis
— Phosphate deficiency
— Hypomagnesemia, hypokalemia
— Critical illness myopathy/neuropathy
— Persistent sedation, opioid load
— Volume overload, undiagnosed pleural effusion
— Cardiac dysfunction, ischemia
— Adrenal insufficiency
— Untreated delirium
— Hypocalcemia (with hyperphosphatemia, or independent)
— Hypomagnesemia (mimics and exacerbates hypocalcemia)
— Respiratory alkalosis (anxiety, sepsis)
— Hyperventilation
— Hypokalemia
— Vitamin D deficiency (most common)
— Hypophosphatemic causes (XLH, TIO)
— Renal osteodystrophy
— Hypophosphatasia (low alkaline phosphatase, distinguishing feature)
— Paget disease (different radiologic pattern)
— Osteoporosis (bone density loss without mineralization defect)
— Mönckeberg medial calcification (DM, CKD, aging)
— Atherosclerotic intimal calcification
— Hyperphosphatemia/CKD-MBD–driven
— Warfarin-induced vascular calcification
— Pseudoxanthoma elasticum
— Uremic pruritus (multifactorial — phosphate, urea, opioid imbalance)
— Secondary hyperparathyroidism contribution
— Iron deficiency
— Cholestasis
— Medication reaction
— Xerosis
— Mannitol, monoclonal gammopathy, severe hyperbilirubinemia, acute leukemia
Key distinction: Osteomalacia vs osteoporosis vs renal osteodystrophy: osteomalacia has defective mineralization (Looser zones, soft bone, pain), osteoporosis has decreased bone quantity (fractures, normal mineralization), renal osteodystrophy combines features and requires bone biopsy in unclear cases.
Board pearl: In an alcoholic admitted for pancreatitis or withdrawal, always check phosphate, magnesium, potassium, and thiamine within 24 hours of starting feeds—refeeding can be lethal.
— Dietary counseling
— Limit phosphate to 800–1000 mg/day
— Avoid hidden phosphate additives (processed meats, colas, cheese spreads, baked goods) — labels say "PHOS"
— Plant-based phosphate (legumes, nuts) less bioavailable than animal/additive phosphate
— Refer to renal dietitian
— Binder regimen tailored to:
— Calcium level (low Ca → calcium-based; high → non-calcium)
— Iron status (deficiency → ferric citrate)
— Pill burden tolerance
— Insurance/cost (calcium acetate cheapest)
— Vitamin D & PTH management
— Repleate 25-OH vitamin D if <30
— Active vitamin D (calcitriol/paricalcitol) for elevated PTH
— Cinacalcet/etelcalcetide for refractory secondary HPT
— Optimize dialysis adequacy if applicable
— Avoid calcium-based binders + active vitamin D combination in adynamic bone disease
— Identify and treat underlying cause (stop tenofovir, treat alcoholism, resect tumor)
— Oral phosphate replacement + active vitamin D for chronic renal wasting
— Burosumab for XLH, TIO (subcutaneous q2–4 weeks)
— Monitor for nephrocalcinosis (annual renal US) and tertiary hyperparathyroidism
— Address concurrent vitamin D deficiency, magnesium deficiency
— Alcohol cessation (counseling, AA, naltrexone)
— Smoking cessation (worsens vascular calcification in CKD)
— Adequate hydration unless on fluid restriction
— Sun exposure / vitamin D for nutritional rickets
— Standard for CKD/dialysis: pneumococcal, hepatitis B (high-dose), influenza, RSV, COVID, shingles
— Annual eye exams (band keratopathy, DM in CKD)
— Fracture risk assessment with DEXA every 1–2 years in CKD-MBD
— Nephrology, primary care, dietitian, dialysis unit, social work
— Medication reconciliation at every visit — binders are commonly missed in transitions
Step 3 management: When transitioning a dialysis patient from hospital to outpatient, explicitly communicate the phosphate binder type, dose, and timing to dialysis unit and PCP—reconciliation errors here are a known patient-safety hot spot.
Board pearl: Dietary phosphate additives (preservatives, often invisible on labels) contribute up to 1000 mg/day in the average American diet and are nearly 100% bioavailable—educate patients to read for "PHOS" ingredients.
— CKD stage 3: Ca, P, PTH every 6–12 months; 25-OH vitamin D yearly
— CKD stage 4: Ca, P every 3–6 months; PTH every 6–12 months
— CKD stage 5/dialysis: Ca, P monthly; PTH every 3 months; alkaline phosphatase every 12 months
— Alkaline phosphatase as marker of bone turnover
— DEXA every 1–2 years if fracture risk
— Phosphate, Ca, Mg, K every 6 hours during IV repletion
— Once stable, daily until normalized × 48 hours
— In refeeding: daily electrolytes × 5–7 days after feeds initiated, then taper to every other day
— Phosphate and alkaline phosphatase every 3 months
— Renal function and urine Ca:Cr every 3–6 months (nephrocalcinosis risk)
— PTH every 6 months (tertiary HPT risk with chronic phosphate therapy)
— Renal ultrasound annually
— Dental exams every 6 months (XLH dental abscess risk)
— Growth charts in pediatric patients
— Take phosphate binders with the first bite of every meal — between meals = ineffective
— Recognize symptoms of hypocalcemia (tingling, cramps) and call provider
— Avoid Fleet enemas, OTC phosphate-containing laxatives if CKD
— Read food labels for phosphate additives ("PHOS-")
— Adherence to dialysis schedule (skipping → phosphate spikes)
— Calcium and vitamin D supplements — only as directed (excess worsens calcification)
— Physical therapy for proximal myopathy in chronic hypophosphatemia or osteomalacia
— Gait training, fall prevention in renal osteodystrophy
— Pediatric orthopedic follow-up for XLH (limb alignment)
— Document binder type and meal timing in MAR
— KCC/CMS quality measures track phosphate control in dialysis units
— Hand-off communication of pending labs and binder changes
CCS pearl: Schedule outpatient follow-up within 1–2 weeks after hospital discharge for hyperphosphatemia/CKD-MBD; binder regimens are often misadministered after discharge and cause readmission.
Step 3 management: When refeeding a high-risk patient, the NICE protocol advises starting at 5–10 kcal/kg/day, advancing to goal over 4–7 days, supplementing thiamine 200–300 mg/day before/during initial feeds, and replacing phosphate, potassium, and magnesium prophylactically.
— IV potassium phosphate is a high-alert medication (Institute for Safe Medication Practices)
— Confusion with potassium chloride leads to fatal arrhythmias
— Always pharmacy-prepared, never bedside admixture
— Maximum rate 7 mmol/hr — exceeding causes hypocalcemia and arrest
— Fleet enema misuse: especially in elderly, CKD, bowel obstruction patients — multiple wrongful-death lawsuits documented
— Hospitals should have order-set warnings; Fleet should not be auto-orderable in CKD
— Binder timing errors: nursing administration not coordinated with meal trays is a common system failure
— Phosphate binders often missing from discharge medication reconciliation
— Dialysis units must receive updated medication list — fax/portal communication required
— Refeeding patients discharged early without electrolyte stabilization can decompensate at home or SNF
— Parathyroidectomy: discuss risk of permanent hypoparathyroidism (lifelong calcium/calcitriol), recurrent laryngeal nerve injury, recurrence
— Burosumab: high cost, infusion-related risks, hyperphosphatemia risk — discuss with patient/family before initiation
— Dialysis initiation in CKD-MBD with multimorbidity: shared decision-making, especially in elderly — palliative care option for those declining dialysis
— XLH treatment involves long-term commitment; engage age-appropriate assent
— Burosumab transition from phosphate/calcitriol regimens requires careful family education
— Severe nutritional rickets in a child should prompt evaluation for nutritional neglect or restrictive feeding practices (e.g., extreme veganism without supplementation)
— Refeeding syndrome in young adult with eating disorder — engage psychiatry and report to appropriate adult protective services if elder/dependent neglect suspected
— Phosphate control is a CMS quality metric for dialysis facilities (% patients with phosphate <5.5)
— Sevelamer/non-calcium binders are costly — prior authorization common
— Patient assistance programs available for burosumab and newer binders
— In advanced CKD with multiple comorbidities, aggressive phosphate management may not improve outcomes — align with patient priorities
— Calciphylaxis carries dismal prognosis; early palliative care consult appropriate
Board pearl: IV phosphate orders must specify rate, total dose in mmol (not mEq), and concurrent K monitoring—ambiguous orders are a documented source of fatal medication errors.
Step 3 management: At discharge from a refeeding hospitalization, ensure: home electrolyte plan, primary care follow-up within 1 week, eating disorder/addiction referral, and clear written instructions on advancing nutrition.
— Alcoholic + admitted + refed → hypophosphatemia (refeeding) — replete BEFORE feeds, give thiamine first
— Vent-dependent + can't wean → check phosphate, Mg, K
— Post-thyroidectomy + tingling + low Ca + high PO₄ → hypoparathyroidism
— Post-thyroidectomy + low Ca + low PO₄ → hungry bone syndrome
— DKA treated → hypophosphatemia, hypokalemia as insulin drives them in
— Lymphoma + chemo + oliguric → tumor lysis (high K, P, uric acid, low Ca)
— Bowed legs + family hx + low PO₄ + high alk phos → X-linked hypophosphatemic rickets (PHEX)
— Adult-onset bone pain, fractures, low PO₄, no family hx → tumor-induced osteomalacia (high FGF-23) — order Ga-68 DOTATATE PET
— Fleet enema in elderly → fatal hyperphosphatemia + hypocalcemia
— IV iron (ferric carboxymaltose) → persistent hypophosphatemia
— Cinacalcet → hypocalcemia, QT prolongation
— Sevelamer → lowers LDL as side benefit; GI side effects
— Calciphylaxis → stop warfarin, give sodium thiosulfate
— XLH first-line → burosumab (not phosphate + calcitriol anymore)
— Normal PO₄: 2.5–4.5 mg/dL
— Severe hypophosphatemia: <1.0
— IV PO₄ max rate: 7 mmol/hr
— Phosphate restriction in CKD: 800–1000 mg/day
— Ca × P product danger zone: >55–70 mg²/dL²
— Refeeding kcal start: 10–20 kcal/kg/day (5–10 in highest risk)
— Cairo-Bishop tumor lysis: uric acid ≥8, K ≥6, PO₄ ≥4.5 (adult), Ca ≤7
— Vascular calcifications on KUB → CKD-MBD
— Brown tumor on X-ray → osteitis fibrosa cystica (secondary HPT)
— Looser zones → osteomalacia
— Rachitic rosary → rickets
— Subperiosteal resorption of phalanges → hyperparathyroidism
— Drugs causing hypophosphatemia: "TIPS-IFI" — Tenofovir, Ifosfamide, Pilocarpine/Pamidronate, Salicylates, Imatinib, Ferric carboxymaltose, Insulin
— Drugs causing hyperphosphatemia: phosphate enemas, vitamin D excess, bisphosphonates, liposomal amphotericin B (assay interference)
Board pearl: "Refeeding pentad" = hypophosphatemia + hypokalemia + hypomagnesemia + thiamine deficiency + fluid overload. Address all five.
Key distinction: Primary HPT (high Ca, low PO₄) vs CKD-driven secondary HPT (low/normal Ca, high PO₄) vs tertiary HPT (high Ca, high PO₄, autonomous PTH after long-standing CKD).
— Stem: Chronic alcoholic admitted for pancreatitis, NPO × 5 days, started on TPN yesterday. Today: confused, weak, RR 24, K 2.9, Mg 1.2, PO₄ 0.8.
— Answer: Stop/slow TPN, give IV thiamine, IV phosphate, IV potassium, IV magnesium
— Trap: Giving glucose without thiamine → Wernicke
— Stem: Septic patient on ventilator for 4 days, hemodynamics improved, but minute ventilation drops on pressure-support trial; phosphate 1.4.
— Answer: Replete phosphate, then reattempt wean
— Stem: New AML, induction chemo yesterday, today oliguric, K 6.2, PO₄ 8.5, Ca 6.8, uric acid 14, Cr 2.5.
— Answer: Aggressive IV fluids, rasburicase, dialysis if oliguric; do NOT give calcium unless symptomatic; avoid K/PO₄ in fluids
— Stem: 82-year-old with CKD stage 4 given two Fleet enemas before colonoscopy; now hypotensive, tetany, PO₄ 13, Ca 6.0.
— Answer: Stop offending agent, IV calcium gluconate for tetany, IV fluids, urgent dialysis
— Stem: 4-year-old boy with bowed legs, short stature; mother had similar findings as child; PO₄ low, Ca normal, PTH normal, alk phos high.
— Answer: Burosumab (anti-FGF-23 antibody) — first-line in 2024 guidelines
— Stem: 50-year-old with progressive bone pain, fractures, low PO₄, high FGF-23, normal renal function.
— Answer: Localize tumor with Ga-68 DOTATATE PET, resect
— Stem: HD patient on warfarin develops painful violaceous lesions on thighs progressing to eschar.
— Answer: Stop warfarin, sodium thiosulfate IV, optimize Ca/P, wound care, cinacalcet
— Stem: ESRD on HD, PO₄ 7.2 despite calcium acetate, Ca 10.8, PTH 850.
— Answer: Switch to non-calcium binder (sevelamer), add cinacalcet (lowers PTH, Ca, and P)
— Stem: Iron-deficiency anemia received IV FCM 2 weeks ago, now bone pain and weakness, PO₄ 1.1.
— Answer: Recognize FCM-induced hypophosphatemia, replete and avoid further FCM (consider ferric derisomaltose alternative)
— Stem: Post-parathyroidectomy day 2, Ca 6.5, PO₄ 1.8, Mg 1.5.
— Answer: IV calcium, oral calcitriol, replete PO₄ and Mg
Step 3 management: Step 3 stems often add an outpatient follow-up question—know that post-discharge phosphate monitoring in refeeding is daily × 1 week, and in CKD-MBD is monthly on dialysis.
Board pearl: When two electrolytes are abnormal, the most common move is to replete magnesium first—it's the cofactor for fixing K and Ca, and refractory phosphate replacement often unmasks unrecognized hypomagnesemia.
Phosphate disorders are diagnosed by combining serum phosphate with calcium, PTH, renal function, and urine phosphate—then treated by identifying the mechanism (shift, intake, excretion, release) and addressing it while repleting or binding phosphate with attention to companion electrolytes, especially calcium and magnesium.
— Hypophosphatemia: Think refeeding, DKA, alcoholism, vent-weaning failure, ferric carboxymaltose, Fanconi, XLH/TIO. Always check Mg and replete it; oral preferred unless <1.0 or symptomatic. IV phosphate max 7 mmol/hr. In refeeding: thiamine before glucose, start at 10 kcal/kg/day, daily electrolytes × 1 week.
— Hyperphosphatemia: 95% of chronic cases are CKD; acute causes are tumor lysis, rhabdomyolysis, hemolysis, and Fleet enemas. CKD-MBD treatment: dietary phosphate restriction (800–1000 mg/day), binders with meals, non-calcium binders preferred with vascular calcification or hypercalcemia, calcimimetics for refractory secondary HPT, parathyroidectomy for tertiary HPT or calciphylaxis.
— Don't miss: Magnesium must be repleted to fix phosphate. Hypocalcemia is the proximate killer in hyperphosphatemia (QT, tetany). Burosumab is first-line for XLH and unresectable tumor-induced osteomalacia. Calciphylaxis requires immediate warfarin discontinuation and sodium thiosulfate.
— Outpatient CKD-MBD follow-up every 1–3 months with phosphate, calcium, PTH
— Transitions of care: explicit communication of binder regimen and timing
— Patient safety: IV potassium phosphate is high-alert; Fleet enemas contraindicated in CKD/elderly
— Refeeding pentad (PO₄, K, Mg, thiamine, fluid) must all be addressed simultaneously
— Burosumab access requires prior authorization and tertiary-center coordination
— Phosphate sits at the intersection of bone, kidney, parathyroid, and FGF-23 axes—every abnormal value is a clue to which axis has failed, and every treatment must respect the others. Mastery is recognizing the mechanism, not memorizing isolated drugs.